Removes the colon and rectum but allows the patient to continue to pass stool through the anus
Users who have achieved significant results may choose to continue at a maintenance dose, take a break and reassess, or adjust their protocol in consultation with a healthcare provider
49557-75-7 403.9 g/mol C14H22CuN6O4 White Lyophilized Powder Multi-pathway profile commonly used as a reference point against single- and dual-pathway compounds in comparative protocols
Medication & Condition Review: Peptide therapy may not be appropriate for patients with certain medical conditions or those taking specific medications
If you have insomnia or just want to get the best possible sleep, DSIP can help
Predrag Sikirics group (School of Medicine, University of Zagreb, 1991 ) Most common experimental dose in animal studies: 10 g/kg intraperitoneally or per os, daily Standard targeted pathways: VEGFR2 angiogenesis, NO synthase , 5-HT2A serotonin receptor, dopamine D2 receptor Clinical program in Croatia halted at Phase 2 (Crohns disease) WADA Prohibited List: added in 2022 to category S0 (Non-Approved Substances) Reference sources (PubMed) Sikiric P